POMPANO BEACH, FLORIDA., May 16,2022 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended March 31, 2022.
BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care market today reported financial results for the year ended December 31, 2021.
BioStem Technologies, Inc. and its subsidiary Blue Tech Industries, Inc. (d/b/a BioStem Life Sciences), a Certified VOSB (Veteran-Owned Small Business), are proud to announce a 2021 Veterans Day Fundraiser to support America's VetDogs®. To honor those who have served our country, BioStem Technologies will be donating 10% of proceeds from all sales November 10-11th, 2021, to America's VetDogs®.
BioStem Technologies, Inc. announces that the Centers for Medicare and Medicaid Services (“CMS”) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (“HCPCS”) “Q” codes. The Company initially filed an application in July of 2020 to have CMS establish a new HCPCS Q code for VENDAJE® and has now received a favorable decision in July of 2021.
BioStem Technologies today announced that it has appointed three key members to its scientific advisory board (SAB). The board, chaired by Kenneth Warrington, Ph.D., welcomes new members Jeffrey Harrison, Ph.D., Daniel Shelly, Ph.D., and Shaun Opie, Ph.D.
